about
Translating pharmacogenomics: challenges on the road to the clinicAssociation between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosisPharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactionsGenetic factors are relevant and independent determinants of antihypertensive drug effects in a multiracial populationGenome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritisErratum to: Making sense of big data in health research: towards an EU action planMaking sense of big data in health research: Towards an EU action planGenetics of rheumatoid arthritis contributes to biology and drug discoveryNon-homologous end-joining pathway associated with occurrence of myocardial infarction: gene set analysis of genome-wide association study data.Flucytosine: correlation between toxicity and pharmacokinetic parameters.5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study.Quantitative analysis of the experimental cytotoxic drug cyclopentenyl cytosine and its metabolite in plasma with HPLC tandem mass spectrometry.Sirolimus and everolimus in kidney transplantation.Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogeneticsExplaining variability in ciclosporin exposure in adult kidney transplant recipients.Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder ChallengeAssociation of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.Impact of chemotherapy-induced nausea and vomiting on quality of life in indonesian patients with gynecologic cancer.Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians.Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification.Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection.Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 studyPharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.Cardiotoxicity of cytotoxic drugs.Marginal increase of sunitinib exposure by grapefruit juice.Clinical pharmacokinetics of tyrosine kinase inhibitors.Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.Integration of sequence data from a Consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk geneRisk assessment in clinical pharmacy.Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.High-quality genotyping data from formalin-fixed, paraffin-embedded tissue on the drug metabolizing enzymes and transporters plus array.Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency.Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study.Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer
P50
Q21092371-8242B73C-E2A3-4732-A18D-72601A94FDD4Q24678827-3C160F6B-964F-4494-8F62-AD7E764F8A77Q27851481-C04A0366-A1A0-47C8-BED8-868518BB4BF5Q28143025-4F3D6C7C-128D-4684-A307-ACB9D706931EQ28259560-D381D258-80DC-4C1A-9598-DB55B08C6830Q28489093-4BB3E865-CACB-438D-8609-793EBA658EDBQ28596148-892FE85F-FDDC-4D2B-ABF5-2FAC29FD35BFQ28597362-5F4AB019-EE19-439D-ADE6-2644789CEBCBQ29417000-56A85264-E63F-4BF8-898C-1AB3BE14F700Q30596587-A726CA5E-4BFC-4CD7-A847-DB12E6EA3B5BQ33331456-806DB40C-CE1E-47B1-B0F2-5EDE6DA70197Q33341541-C4043FEC-5D0B-479C-85E9-0BB082BD3807Q33355563-970CB88A-3ABC-4742-8401-BE71D3B59B0DQ33423446-CD7433C8-8D03-4D81-8A68-DBBF19CAA1A1Q33423611-D310C49F-093F-4E9C-A6F8-68671751E6C8Q33437427-9CC0C84E-9A7E-48E4-BD34-8AA75B85113EQ33834310-8B858B62-FF7B-4AA7-AA33-A7DE58BA0CDDQ33847140-9D21062F-E818-4066-8F20-EFE911082597Q33855802-D64ED07E-9738-4CFE-B788-6484F2815B96Q33992722-D16F8C32-CA08-4A05-9993-5700ED1DD5EEQ34048307-7FF627EE-A000-4B2C-BC13-C518733596D4Q34073722-2EDF9EDC-3CC6-46A3-86F6-4EE7D937511EQ34090514-0A7494F3-FED2-4830-8DD3-111C5CB93A33Q34216613-3548F7D5-E4BE-4C52-BE62-5FBD960A8844Q34239753-B548A987-D12E-4056-B2A5-49947324AAA5Q34255174-B0035079-FF29-4666-B6FA-9C9D51AEABEBQ34466353-F03775A2-B082-4421-9F72-3BC43C427CCAQ34467460-78EB7988-EF53-4C4F-B4DC-A007B6A8A39FQ34546371-FD7CD1E8-6326-44C7-9374-16B7A6B10572Q34594877-598EF56A-E07C-4281-A9A8-D42E3CBD2B9BQ34611569-C9F33B8B-1EDD-4130-B0E6-BB5665E1C3DFQ34719466-AB4347A1-278D-4643-837D-718079079BEDQ34797430-4238CAA7-9328-42E4-B2D4-971A5C6C9434Q35092644-21B0D6E1-6570-42E0-87BF-8E71E77106ADQ35168994-5E3F1984-7D68-4544-8C8D-50C561F15D09Q35178065-2F0C1298-5D4E-4E7B-8379-7C53CE6DF2ADQ35531556-3A22E18F-4C34-4B54-B637-B6D545B5AC6EQ35563540-97AF2F7E-78F3-41CD-9579-2CA6DBDE0BE0Q35644029-D5BE6DDA-2DBC-42A5-AFCD-7F48F4E45353Q35722688-62A653FA-480C-4FA5-9E96-251477584FE8
P50
description
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Henk-Jan Guchelaar
@ast
Henk-Jan Guchelaar
@en
Henk-Jan Guchelaar
@es
Henk-Jan Guchelaar
@nl
type
label
Henk-Jan Guchelaar
@ast
Henk-Jan Guchelaar
@en
Henk-Jan Guchelaar
@es
Henk-Jan Guchelaar
@nl
altLabel
Guchelaar HJ
@en
prefLabel
Henk-Jan Guchelaar
@ast
Henk-Jan Guchelaar
@en
Henk-Jan Guchelaar
@es
Henk-Jan Guchelaar
@nl
P1006
P214
P1006
P106
P21
P214
P2798
P31
P496
0000-0002-7085-1383
P7859
viaf-280534653